Busulfan

From Wikipedia, the free encyclopedia

Busulfan
Systematic (IUPAC) name
1,4-bis(methylsulfonyloxy)butane
Identifiers
CAS number 55-98-1
ATC code L01AB01
PubChem 2478
DrugBank APRD00664
Chemical data
Formula C6H14O6S2 
Mol. mass 246.304 g/mol
Pharmacokinetic data
Bioavailability 80% (oral)
Protein binding 32.4%
Metabolism Hepatic
Half life 2.5 hours
Excretion  ?
Therapeutic considerations
Licence data

EU US

Pregnancy cat.

?

Legal status

Prescription only

Routes Oral, parenteral

Busulfan is a chemotherapy drug that is an alkylating agent (slows the growth of cancer cells). It is marketed in the U.S. by GlaxoSmithKline under the brand name Myleran, and has been in clinical use since 1959. Its chemical designation is 1,4-Butanediol dimethanesulfonate.

Contents

[edit] Uses

Currently, its main uses are in bone marrow transplantation, especially in chronic myelogenous leukemia (CML), where it is used as a conditioning drug.

The drug was recently used in a study to examine the role of platelet-transported serotonin in liver regeneration.[1]

Busulfan is now available in an IV formulation marketed as Busulfex by PDL BioPharma, Inc.

[edit] Toxicity and side effects

Toxicity may include pulmonary fibrosis and hyperpigmentation. 1,4-Butanediol dimethanesulfonate is listed by the IARC as a Group 1 carcinogen.

Busulfan also induces thrombocytopenia, a condition of lowered blood platelet count and activity.

[edit] References

  1. ^ Lesurtel M, Graf R, Aleil B, Walther D, Tian Y, Jochum W, Gachet C, Bader M, Clavien P (2006). "Platelet-derived serotonin mediates liver regeneration". Science 312 (5770): 104–7. PMID 16601191. 

[edit] External links

  • Myleran (PDF prescribing information)
  • Busulfex (PDF prescribing information)


In other languages